Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.53 |
| ▸ | PNLIP | P16233 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.45 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874164 | 1.00 | PTPN1 (0.53) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL22874137 | 1.00 | PTPN1 (0.53) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL22874138 | 1.00 | PTPN1 (0.53) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL15874513 | 0.88 | PTPN1 (0.55) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL25431893 | 0.88 | PTPN1 (0.55) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL25399107 | 0.88 | PTPN1 (0.55) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL15874514 | 0.88 | PTPN1 (0.55) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL25395422 | 0.88 | PTPN1 (0.55) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL24264493 | 0.84 | PTPN1 (0.56) | PTPN1PNLIPPTPN2POLBMAPT | |
| SCHEMBL13722523 | 0.84 | PTPN1 (0.56) | PTPN1PNLIPPTPN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062687-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH & CIE (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12486499-B2 | Biocatalytic method for the controlled degradation of terpene compounds | FIRMENICH SA (CH) | 2025-12-02 | — | — | US | disclosed |
| US-20250171391-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | FIRMENICH SA (CH) | 2025-05-29 | — | — | US | disclosed |
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| WO-2021005097-A9 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021005097-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2021-01-14 | — | — | WO | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-9540353-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | PTPN1 17/4885PNLIP 501/4885PTPN2 65/4885 |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1A, PPM1D, PPP1R1B | PTPN1 11/4885PNLIP 569/4885PTPN2 59/4885 |
| US-20260062687-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | CYP51A1, BBOX1, ERG28 | PTPN1 4325/4885PNLIP 733/4885PTPN2 4392/4885 |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | PTPN1 17/4885PNLIP 501/4885PTPN2 65/4885 |
| US-20250171391-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | POR, NDUFV1, NDUFV2 | PTPN1 4332/4885PNLIP 1966/4885PTPN2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.